* Health Catalyst Inc HCAT.OQ HCAT.O is expected to show
a
rise in quarterly revenue when it reports results on August 7
for the period ending June 30 2024
* The South Jordan Utah-based company is expected to report
a
2.4% increase in revenue to $75.005 million from $73.21 million
a year ago, according to the mean estimate from 15 analysts,
based on LSEG data.The company's guidance on May 9 2024, for the
period ended June 30, was for revenue between $73.50 million and
$76.50 million.
* LSEG's mean analyst estimate for Health Catalyst Inc is
for
earnings of 8 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Health
Catalyst
Inc is $11.00, above its last closing price of $6.02.
The company's guidance on May 9 2024 for the period ended June
30 was for Earnings before Interest, Taxes, Depreciation and
Amortization of between USD73.5 million and USD7 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 0.03 0.03 0.05 Beat 79
Dec. 31 2024 0.01 0.00 0.02 Beat 2,700
Sep. 30 2023 0.00 -0.02 0.03 Beat 275.6
Jun. 30 2023 -0.01 0.00 0.05 Beat 1,447.
7
Mar. -0.04 -0.04 0.05 Beat 222.9
31 2023
Dec. 31 2022 -0.11 -0.11 -0.05 Beat 55.8
Sep. 30 2022 -0.18 -0.19 -0.13 Beat 32.8
Jun. 30 2022 -0.09 -0.10 -0.03 Beat 70.2
This summary was machine generated August 6 at 02:55 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)